share_log

天津发展(00882)：力生制药2023年度净利润3.62亿元，同比增加286.47%

Tianjin Development (00882): Lisheng Pharmaceutical's net profit for 2023 was 362 million yuan, an increase of 286.47% over the previous year

Zhitong Finance ·  Feb 27 13:04

Tianjin Development (00882) announced Lisheng Pharmaceutical (002393.SZ) 2023, a non-wholly-owned subsidiary of the company...

According to Zhitong Finance App News, Tianjin Development (00882) released the 2023 annual performance report of Lisheng Pharmaceutical (002393.SZ), a non-wholly-owned subsidiary of the company, with total operating revenue of 1.153 billion yuan (RMB, same below), up 0.56% year on year; net profit attributable to shareholders of listed companies was 362 million yuan, an increase of 286.47% year on year; basic earnings per share were 1.96 yuan.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment